Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy

被引:15
作者
Foster, AE
Gottlieb, DJ
Marangolo, M
Bartlett, A
Li, YC
Barton, GW
Romagnoli, JA
Bradstock, KF [1 ]
机构
[1] Westmead Hosp, Blood & Marrow Transplant Serv, Westmead, NSW 2145, Australia
[2] Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW 2006, Australia
[3] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
[4] Univ Sydney, Dept Chem Engn, Sydney, NSW 2006, Australia
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2003年 / 12卷 / 01期
关键词
D O I
10.1089/152581603321210172
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adoptive transfer of donor-derived cytomegalovirus (CMV)-specific cytotoxic T cell (CTL) clones can restore immunity in allogeneic stem cell transplant recipients, providing protection against CMV disease. Current methods for selecting and expanding CMV-specific T cell clones are technically difficult, making adoptive T cell therapy impractical for routine clinical use. In this study, we describe a method for ex vivo generation and expansion of high-purity CMV-specific CTL using peptide-pulsed dendritic cells as antigen-presenting cells. Generation of CMV-specific CTL in numbers sufficient for clinical use in the time span of 4 weeks was accomplished in 6 of 8 CMV-seropositive donors. Examination of pp65 specificity by HLA/peptide tetramer staining demonstrated that a purity of greater than 95% peptide-specific cells could be obtained after two weekly stimulations and retained after further expansion for 3-4 weeks. Median expansion of total cell number was greater than 500-fold and expansion of peptide-specific CTL by tetramer staining was greater than 1.7x10(5)-fold. Four weeks after initiating CTL culture, we were able to generate greater than 109 total cells that specifically lysed target cells loaded with CMV peptide and cells infected with CMV. This simple and rapid method for generating high-purity CMV-specific CTL for adoptive immunotherapy is currently being examined for routine clinical use for allogeneic stem cell transplantation.
引用
收藏
页码:93 / 105
页数:13
相关论文
共 44 条
[31]   Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients [J].
Rooney, CM ;
Smith, CA ;
Ng, CYC ;
Loftin, SK ;
Sixbey, JW ;
Gan, YJ ;
Srivastava, DK ;
Bowman, LC ;
Krance, RA ;
Brenner, MK ;
Heslop, HE .
BLOOD, 1998, 92 (05) :1549-1555
[32]   THE MONOCLONAL-ANTIBODY CR11-351 DISCRIMINATES HLA-A2 VARIANTS IDENTIFIED BY T-CELLS [J].
RUSSO, C ;
NG, AK ;
PELLEGRINO, MA ;
FERRONE, S .
IMMUNOGENETICS, 1983, 18 (01) :23-35
[33]   Two subsets of memory T lymphocytes with distinct homing potentials and effector functions [J].
Sallusto, F ;
Lenig, D ;
Förster, R ;
Lipp, M ;
Lanzavecchia, A .
NATURE, 1999, 401 (6754) :708-712
[34]   GANCICLOVIR SENSITIVITY OF CYTOMEGALOVIRUS AT DIAGNOSIS AND DURING TREATMENT OF CYTOMEGALOVIRUS PNEUMONIA IN MARROW TRANSPLANT RECIPIENTS [J].
SLAVIN, MA ;
BINDRA, RR ;
GLEAVES, CA ;
PETTINGER, MB ;
BOWDEN, RA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (06) :1360-1363
[35]  
Solache A, 1999, J IMMUNOL, V163, P5512
[36]   Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65 [J].
Sun, Q ;
Pollok, KE ;
Burton, RL ;
Dai, LJ ;
Britt, W ;
Emanuel, DJ ;
Lucas, KG .
BLOOD, 1999, 94 (09) :3242-3250
[37]   Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers [J].
Szmania, S ;
Galloway, A ;
Bruorton, M ;
Musk, P ;
Aubert, G ;
Arthur, A ;
Pyle, H ;
Hensel, N ;
Ta, N ;
Lamb, L ;
Dodi, T ;
Madrigal, A ;
Barrett, J ;
Henslee-Downey, J ;
van Rhee, F .
BLOOD, 2001, 98 (03) :505-512
[38]   Selective ex vivo expansion of cytomegalovirus-specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide [J].
Vannucchi, AM ;
Glinz, S ;
Bosi, A ;
Caporale, R ;
Rossi-Ferrini, P .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) :479-482
[39]   A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants [J].
Verdonck, LF ;
Dekker, AW ;
RozenbergArska, M ;
vandenHoek, MR .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :901-907
[40]   RECONSTITUTION OF CELLULAR-IMMUNITY AGAINST CYTOMEGALOVIRUS IN RECIPIENTS OF ALLOGENEIC BONE-MARROW BY TRANSFER OF T-CELL CLONES FROM THE DONOR [J].
WALTER, EA ;
GREENBERG, PD ;
GILBERT, MJ ;
FINCH, RJ ;
WATANABE, KS ;
THOMAS, ED ;
RIDDELL, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (16) :1038-1044